China’s biopharmaceutical sector is seeing an uptick in deal-making, with sovereign wealth funds from Singapore and the United Arab Emirates joining Chinese state-backed investors to back next-generation drug developers.
Shanghai-based Everest Medicines agreed to spend US$250 million to acquire a Singapore company holding rights to 14 chronic-disease treatments across the Asia-Pacific region, according to a stock exchange filing on Wednesday.
Its Singapore unit will acquire 100 per cent of…
China biotech flow picks up as Everest seals US$250 million deal
